An investigational pill called daraxonrasib nearly doubled overall survival for patients with advanced KRAS-mutant pancreatic cancer in a Phase 3 trial [1].
The results represent a potential shift in treatment for one of the most lethal forms of cancer, which has historically lacked effective late-stage therapies [2].
Developed by Revolution Medicines, daraxonrasib is a KRAS G12C inhibitor [1]. The drug targets a specific genetic mutation to slow the progression of the disease. Results from the trial were announced in April 2026 [3].
According to data from the trial, the drug was shown to almost double the survival time for pancreatic cancer patients compared to those receiving chemotherapy [4]. Researchers said the findings were an "unprecedented" advance in the treatment of the disease [3].
Pancreatic cancer is often difficult to treat because of its aggressive nature and the lack of targeted options for advanced stages. Daraxonrasib improved survival outcomes in advanced pancreatic cancer, offering new hope for patients with KRAS-mutant disease [5].
The drug is administered as a pill, which may offer a different quality of life compared to traditional intravenous chemotherapy. The Phase 3 trial focused on patients in the U.S. who had advanced stages of the disease [6].
While chemotherapy remains a standard of care, the ability to target the KRAS G12C mutation allows for a more precise medical intervention. The data suggests that this targeted approach is significantly more effective at extending life than broad-spectrum chemotherapy [7].
“the drug was shown to almost double the survival time for pancreatic cancer patients”
The success of daraxonrasib indicates that precision medicine—specifically targeting the KRAS G12C mutation—is more effective for late-stage pancreatic cancer than traditional chemotherapy. By nearly doubling survival times, this drug could redefine the standard of care for a specific genetic subset of patients, moving the treatment model from general cytotoxic therapy toward targeted molecular inhibition.
